162 related articles for article (PubMed ID: 34853037)
1. Are CRISPR Screens Providing the Next Generation of Therapeutic Targets?
Vazquez F; Sellers WR
Cancer Res; 2021 Dec; 81(23):5806-5809. PubMed ID: 34853037
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-Based Positive Screens for Cancer-Related Traits.
Slipek NJ; Varshney J; Largaespada DA
Methods Mol Biol; 2019; 1907():137-144. PubMed ID: 30542997
[TBL] [Abstract][Full Text] [Related]
3. Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal.
Krill-Burger JM; Dempster JM; Borah AA; Paolella BR; Root DE; Golub TR; Boehm JS; Hahn WC; McFarland JM; Vazquez F; Tsherniak A
Genome Biol; 2023 Aug; 24(1):192. PubMed ID: 37612728
[TBL] [Abstract][Full Text] [Related]
4. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Behan FM; Iorio F; Picco G; Gonçalves E; Beaver CM; Migliardi G; Santos R; Rao Y; Sassi F; Pinnelli M; Ansari R; Harper S; Jackson DA; McRae R; Pooley R; Wilkinson P; van der Meer D; Dow D; Buser-Doepner C; Bertotti A; Trusolino L; Stronach EA; Saez-Rodriguez J; Yusa K; Garnett MJ
Nature; 2019 Apr; 568(7753):511-516. PubMed ID: 30971826
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide CRISPR screens for the identification of therapeutic targets for cancer treatment.
Xue VW; Wong SCC; Cho WCS
Expert Opin Ther Targets; 2020 Nov; 24(11):1147-1158. PubMed ID: 32893711
[TBL] [Abstract][Full Text] [Related]
6. A CRISPR Platform for Targeted In Vivo Screens.
Maranda V; Zhang Y; Vizeacoumar FS; Freywald A; Vizeacoumar FJ
Methods Mol Biol; 2023; 2614():397-409. PubMed ID: 36587138
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization.
Pacini C; Duncan E; Gonçalves E; Gilbert J; Bhosle S; Horswell S; Karakoc E; Lightfoot H; Curry E; Muyas F; Bouaboula M; Pedamallu CS; Cortes-Ciriano I; Behan FM; Zalmas LP; Barthorpe A; Francies H; Rowley S; Pollard J; Beltrao P; Parts L; Iorio F; Garnett MJ
Cancer Cell; 2024 Feb; 42(2):301-316.e9. PubMed ID: 38215750
[TBL] [Abstract][Full Text] [Related]
8. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
9. Synthetic lethality as an engine for cancer drug target discovery.
Huang A; Garraway LA; Ashworth A; Weber B
Nat Rev Drug Discov; 2020 Jan; 19(1):23-38. PubMed ID: 31712683
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas13 System as a Promising and Versatile Tool for Cancer Diagnosis, Therapy, and Research.
Palaz F; Kalkan AK; Can Ö; Demir AN; Tozluyurt A; Özcan A; Ozsoz M
ACS Synth Biol; 2021 Jun; 10(6):1245-1267. PubMed ID: 34037380
[TBL] [Abstract][Full Text] [Related]
11. Hallmarks of cancer: The CRISPR generation.
Moses C; Garcia-Bloj B; Harvey AR; Blancafort P
Eur J Cancer; 2018 Apr; 93():10-18. PubMed ID: 29433054
[TBL] [Abstract][Full Text] [Related]
12. CRISPR screen in mechanism and target discovery for cancer immunotherapy.
Liu D; Zhao X; Tang A; Xu X; Liu S; Zha L; Ma W; Zheng J; Shi M
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188378. PubMed ID: 32413572
[TBL] [Abstract][Full Text] [Related]
13. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.
Meyers RM; Bryan JG; McFarland JM; Weir BA; Sizemore AE; Xu H; Dharia NV; Montgomery PG; Cowley GS; Pantel S; Goodale A; Lee Y; Ali LD; Jiang G; Lubonja R; Harrington WF; Strickland M; Wu T; Hawes DC; Zhivich VA; Wyatt MR; Kalani Z; Chang JJ; Okamoto M; Stegmaier K; Golub TR; Boehm JS; Vazquez F; Root DE; Hahn WC; Tsherniak A
Nat Genet; 2017 Dec; 49(12):1779-1784. PubMed ID: 29083409
[TBL] [Abstract][Full Text] [Related]
14. PICKLES: the database of pooled in-vitro CRISPR knockout library essentiality screens.
Lenoir WF; Lim TL; Hart T
Nucleic Acids Res; 2018 Jan; 46(D1):D776-D780. PubMed ID: 29077937
[TBL] [Abstract][Full Text] [Related]
15. Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets.
Dempster JM; Pacini C; Pantel S; Behan FM; Green T; Krill-Burger J; Beaver CM; Younger ST; Zhivich V; Najgebauer H; Allen F; Gonçalves E; Shepherd R; Doench JG; Yusa K; Vazquez F; Parts L; Boehm JS; Golub TR; Hahn WC; Root DE; Garnett MJ; Tsherniak A; Iorio F
Nat Commun; 2019 Dec; 10(1):5817. PubMed ID: 31862961
[TBL] [Abstract][Full Text] [Related]
16. Exploring the genetic space of the DNA damage response for cancer therapy through CRISPR-based screens.
Wilson J; Loizou JI
Mol Oncol; 2022 Nov; 16(21):3778-3791. PubMed ID: 35708734
[TBL] [Abstract][Full Text] [Related]
17. Multiplex enCas12a screens detect functional buffering among paralogs otherwise masked in monogenic Cas9 knockout screens.
Dede M; McLaughlin M; Kim E; Hart T
Genome Biol; 2020 Oct; 21(1):262. PubMed ID: 33059726
[TBL] [Abstract][Full Text] [Related]
18. Inferring cancer dependencies on metabolic genes from large-scale genetic screens.
Lagziel S; Lee WD; Shlomi T
BMC Biol; 2019 Apr; 17(1):37. PubMed ID: 31039782
[TBL] [Abstract][Full Text] [Related]
19. Genome-Wide CRISPR/Cas9 Screening for Identification of Cancer Genes in Cell Lines.
Adelmann CH; Wang T; Sabatini DM; Lander ES
Methods Mol Biol; 2019; 1907():125-136. PubMed ID: 30542996
[TBL] [Abstract][Full Text] [Related]
20. Pooled CRISPR-Based Genetic Screens in Mammalian Cells.
Chan K; Tong AHY; Brown KR; Mero P; Moffat J
J Vis Exp; 2019 Sep; (151):. PubMed ID: 31545321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
